On Jun 29, 2018 Raymond James Analyzed Intercept Pharmaceuticals (NASDAQ:ICPT) with $122 Target.

June 29, 2018 - By Ronnie Lemelle

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Corporate Logo

Big Money Sentiment decreased to 1.15 in 2018 Q1. It has change of 0.16, from 2017Q4’s 1.31. The ratio fall due to Intercept Pharmaceuticals, Inc. positioning: 24 sold and 35 reduced. 20 funds took stakes and 48 increased stakes. Investors holded 17.97 million in 2017Q4 but now own 18.85 million shares or 4.89% more.

Jane Street Limited Liability Company holds 0% or 22,429 shs in its capital. Public Employees Retirement Systems Of Ohio has 7,038 shs. New York State Common Retirement Fund holds 40,300 shs. Ontario – Canada-based Royal Bankshares Of Canada has invested 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Dsc Advsrs Limited Partnership reported 3,500 shs. Citigroup holds 0% of its capital in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 2,057 shs. Florida-based Raymond James And has invested 0.01% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). State Board Of Administration Of Florida Retirement reported 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). 3,831 are owned by Amalgamated National Bank. The Iowa-based Principal Financial Grp Inc Inc Inc has invested 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Aperio Limited Liability Co stated it has 0% of its capital in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Profund Advisors Ltd owns 5,940 shs for 0.01% of their capital. 42,330 were accumulated by Citadel Llc. Janney Montgomery Scott Limited Liability has 7,137 shs for 0% of their capital. Federated Invsts Pa has 0% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT).

What Price Target Has Raymond James Given Intercept Pharmaceuticals (NASDAQ:ICPT)

Investment firm Raymond James has started coverage of ICPT’s shares on Thursday morning. Raymond James’s Professional analysts have has “Strong Buy” rating while giving it the PT at $122.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Ratings Coverage

Total analysts of 7 have positions in Intercept Pharma (NASDAQ:ICPT) as follows: 5 rated it a “Buy”, 1 with “Sell” and 1 with “Hold”. The positive are 71%. Since January 22, 2018 according to StockzIntelligence Inc Intercept Pharma has 10 analyst reports. On Thursday, January 25 the stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) earned “Buy” rating by Wedbush. On Thursday, February 1 the stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) earned “Buy” rating by Wedbush. On Monday, February 12 the firm has “Buy” rating given by Wedbush. On Thursday, February 15 the stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) earned “Outperform” rating by BMO Capital Markets. In Monday, January 22 report Credit Suisse maintained it with “Buy” rating and $167.0 target. The stock rating was maintained by Wells Fargo with “Hold” on Tuesday, February 13. On Tuesday, April 17 the rating was maintained by Wedbush with “Outperform”. On Wednesday, February 7 the rating was downgraded by Goldman Sachs to “Sell”.

Ticker’s shares touched $84.13 during the last trading session after 5.29% change.Currently Intercept Pharmaceuticals, Inc. is downtrending after 38.34% change in last June 29, 2017. ICPT has 264,180 shares volume. The stock underperformed the S&P 500 by 50.91%.

On July, 30. Investors wait Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) to reveal its quarterly earnings, according to Zacks. This year’s earnings per share analyst estimate is anticipated to be $-2.94. That is 15.03 % up compareed to $-3.46 earnings per share for last year. After $-3.22 EPS report previous quarter, Wall Street now forecasts -8.70 % EPS growth of Intercept Pharmaceuticals, Inc..

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada.The firm is valued at $2.49 billion. The Company’s lead product candidate is obeticholic acid , a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).Last it reported negative earnings. The firm is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, and biliary atresia.

For more Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) news published briefly go to: Fool.com, Fool.com, Seekingalpha.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Viking Therapeutics, Buy the Dip?” published on June 26, 2018, “Why Viking Therapeutics Stock Is On Fire Today” on May 31, 2018, “Intercept Pharmaceuticals: Buyout Speculation Stokes Shares” with a publish date: June 12, 2018, “Intercept’s Obeticholic Acid Therapy And NASH: The Scientific Truth Is That Every Cloud Has A Silver Lining” and the last “Intercept And Obeticholic Acid Therapy: Discerning Scientific Facts From Fallacies On Cholestatic Liver Diseases” with publication date: June 12, 2018.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.